Orbimed Advisors LLC Adc Therapeutics Sa Transaction History
Orbimed Advisors LLC
- $3.69 Billion
- Q4 2024
A detailed history of Orbimed Advisors LLC transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Orbimed Advisors LLC holds 5,968,451 shares of ADCT stock, worth $11 Million. This represents 0.32% of its overall portfolio holdings.
Number of Shares
5,968,451
Previous 4,533,801
31.64%
Holding current value
$11 Million
Previous $14.3 Million
16.83%
% of portfolio
0.32%
Previous 0.34%
Shares
3 transactions
Others Institutions Holding ADCT
# of Institutions
85Shares Held
55.3MCall Options Held
24.1KPut Options Held
44.7K-
Redmile Group, LLC San Francisco, CA15.7MShares$28.8 Million2.44% of portfolio
-
Prosight Management, LP Dallas, TX9.52MShares$17.5 Million5.62% of portfolio
-
Morgan Stanley New York, NY3.96MShares$7.28 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$6.54 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA1.93MShares$3.56 Million0.03% of portfolio
About ADC Therapeutics SA
- Ticker ADCT
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,645,296
- Market Cap $143M
- Description
- ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...